Royalty Report: Drugs, Cancer, Therapeutic – Collection: 275831

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 275831

License Grant
Licensor agrees to grant to the United Kingdom Licensee, pursuant to the License Agreement (i) a non-exclusive royalty-free license to develop the Licensed Product for any Indication under the Licensor Know-how and Licensor Patent as well as (ii) an exclusive, royalty-bearing license to conduct Commercialization Activities, including the right to sublicense, within the Licensee Territory for any Indication under the Licensor Patent, Licensor Know-how and the Licensed Trademark. In accordance with the Parties’ agreement to extend the licensed territory, the Parties agree that the License Agreement related to all Patents and Patent Applications Controlled by Licensor in the European Territory which Cover the Licensed Products shall be amended and incorporated herein by reference, to include all Patents and Patent Applications Controlled by Licensor in the Licensee Territory (the Licensor Patent).

Licensee and Licensor entered into the Original Collaboration and License Agreement which, among other things, provides for certain terms and conditions relating to the conduct of certain development activities for the purpose of obtaining Regulatory Approvals in the United States of America and its territories and possessions (“US”) and in the European Territory for the Initial Products in certain indications, including the ADT Indication and the PIN Indication, for Commercialization Activities by Licensee of the Licensed Product in the European Territory.

Licensee and Licensor have agreed to collaborate in the design of the Additional Phase III Study to gain Regulatory Approvals by the FDA and the EMEA, and to get input from the FDA on the protocol for the Additional Phase III Study to better ascertain the FDA’s commitment that the Additional Phase III Study will be sufficient to support Regulatory Approval in the US, assuming the study achieves the agreed upon efficacy endpoints and the product candidate is determined to be safe.

Licensor has sought from Licensee an Additional Milestone Payment in consideration of additional rights granted hereunder, including but not limited to expanding Licensee’s territory and co-promoting the Licensed Product in the ADT Indication in the US; and Licensee desires to effect payment in respect thereof.

License Property
Licensor Patent shall have the meaning prescribed to it in this First Amendment. For the avoidance of doubt, Licensor Patent, as defined herein, shall supersede the definition of Licensor Patent defined in the License Agreement. The list of the Licensor Patent identified are International Patents.

The Licensed Product shall mean Toremifene 80 mg for the prevention of bone fractures and serious side effects in men with prostate cancer on androgen deprivation therapy (ADT), identified in the License Agreement as being within the scope of the ADT Indication.

Toremifene 20 mg is in an ongoing pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia (PIN).

Additional Phase III Study – Phase III Clinical Study of toremifene 80mg for the ADT Indication be conducted by Licensor for the obtaining of Regulatory Approval in the ADT Indication in the US.

Toremifene is a selective estrogen receptor modulator, or SERM, developed by GTx as a daily tablet for the treatment of the multiple estrogen related side effects of androgen deprivation therapy for advanced prostate cancer and for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN). Toremifene was designed to bind to and selectively modulate estrogen receptors depending on the tissue type.

Field of Use
This agreement pertains to the drug industry in the Field that shall have the meaning relating to the side effects of ADT in men with prostate cancer include among others bone fractures.

The development and commercialization of toremifene 80 mg is for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg is for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).

IPSCIO Record ID: 238982

License Grant
University hereby grants to Licensee an exclusive, worldwide right and license, with the right to grant Sublicenses and to permit Sub-sublicenses to practice under and use the Licensed Patents and the Licensed Technology to make, have made, use, market, sell, have sold, import, distribute, and offer for sale any Licensed Product, Licensed Process or Generic Product. University hereby agrees, subject to the terms and conditions herein contained, that the term 'exclusive' means that University shall not grant any other license to any third party or take any action inconsistent with the rights granted to Licensee under this Agreement relating to the Licensed Patents or Licensed Technology.
License Property
Licensed Patents shall mean
6,265,448 – Method for chemoprevention of prostate cancer
6,413,533 – Method for chemoprevention of prostate cancer
6,413,534 – Method for chemoprevention of prostate cancer
6,410,043 – Method for chemoprevention of prostate cancer
6,413,535 – Method for chemoprevention of prostate cancer

Licensed Technology shall mean any technology, trade secrets, methods, processes, know-how, show-how, data, information, or results relating to the patent applications, developed by the Contributors and owned by University, including the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent or pharmaceutical preparation comprising an anti-estrogen or SERM, including, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis.

Field of Use
Patents relate to toremifene for the reduction in the incidence of prostate cancer in men with high grade PIN and its composition of matter and method of use patents and patent applications relating to Andarine to market, distribute and sell licensed products.

IPSCIO Record ID: 203383

License Grant
The Licensor of Finland grants an exclusive right and license, with the right to grant sublicenses, under Licensor Patent Rights and Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the North American Territory and in Japan in the Field;
– a non-exclusive right and license, with the right to grant sublicenses, under Licensor Patent Rights and
Licensor Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the ROW Territory for exclusive use in the Field;
– a non-exclusive license, under the Licensor Patents and Know-How, to perform research and preclinical development activities using the Powder.
License Property
The product means any pharmaceutical product for human use within the Field containing Toremifene as a therapeutically active ingredient.

Toremifene' shall mean [toremifene citrate and/or 4-chloro-l, 2 diphenyl-1-(4(2-(N,N-dimethylamino)-ethoxyl) – phenyl] -I-butene].

Toremifene is a selective estrogen receptor modulator (SERM) of the triphenylethylene group related to tamoxifen which opposes the actions of estrogens like estradiol in the body and is approved for use in the treatment of advanced (metastatic) breast cancer.

Field of Use
The field means the prevention and treatment of prostate cancer, which shall mean for purposes hereof preventing prostate carcinogenesis; suppressing or inhibiting prostate cancer; reducing the risk of developing prostate cancer; increasing the survival rate of a subject with prostate cancer; and treating prostate cancer.

IPSCIO Record ID: 203339

License Grant
The Licensor of Finland grants to Licensee an exclusive right and license, with the right to grant sublicenses under Licensor Patent Rights and Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the Field in the Licensee Territory, except in the Licensor Field in the Licensor Territory; and a non-exclusive right and license, with the right to grant sublicenses, under the Licensor Patents and Know-How, to perform research and preclinical development activities, using the Powder to be provided to Licensor, except in the Licensor Field in the Licensee Territory.
License Property
The Product shall mean any pharmaceutical product for human use within the Field containing Toremifene as a therapeutically active ingredient.

The Fareston Product shall mean the Orion Product in 60 mg tablet form containing Toremifene that was promoted in the USA under the brand name Fareston by Shire prior to the Restatement Date for use in the Breast Cancer Field.

Toremifene shall mean [tore mi f ene citrate and/or the Z-isomer of 4-chloro-1, 2 diphenyl-1-(4-(2-(N,N-dimethylamino)-ethoxy) – phenyl]- 1 -butene].

Field of Use
The field means all uses of a Product in humans, with a current use of treatment of prostate cancer. The Parties expressly acknowledge that the use of Product in the field of animal health is excluded from the scope of this Agreement.

IPSCIO Record ID: 256112

License Grant
Pursuant to the Third Amended SLA, as of the Effective Date, Australian Licensee has assumed control of the regulatory and clinical development program for SUBA-Itraconazole BCCNS and immediately assumed responsibility for all expenses related to exploiting the SUBA-Itraconazole product in the BCCNS field, provided that the Licensor continues to be responsible for all liabilities related to the product in the United States prior to the Effective Date. The Third Amended SLA will continue in effect on an exclusive basis in the Territory on substantially the same terms as were provided for under the Second Amended SLA, except as described below.

Licensee will continue to provide quantities of Product drug and placebo oral capsules without charge for the Licensor’s SUBA-Itraconazole Prostate clinical studies and for future indications as agreed to by the parties.

License Property
The intellectual property is SUBA®-Itraconazole for the treatment of basal cell carcinoma nevus syndrome (SUBA-Itraconazole BCCNS).
Field of Use
The field covered by the Third Amended SLA was amended to specifically include only the following indications  any prostate cancer, prostatic intraepithelial neoplasia and benign prostatic hyperplasia,  any lung cancer and atypical adenomatous hyperplasia, and  familial adenomatous polyposis, colorectal polyps and Barett’s esophagus.

SUBA-Itraconazole Capsules is for the treatment of human cancer via oral administration.

IPSCIO Record ID: 369284

License Grant
University grants Licensee and its affiliated companies and exclusive License under the Licensed Patents and a non-exclusive license under the know-how in the field of use to make, have made, use, sell, offer to sell and import Licensed Products and perform Licensed Services in the Licensed Territory. If any affiliated company exercises rights under this Agreement, such affiliated company shall be bound by all terms and conditions of this Agreement, including but not limited to indemnity and insurance provisions and royalty payments. In addition, Licensee shall remain fully liable to University for all acts and obligations of affiliated company such that acts of the affiliated company shall be considered acts of the Licensee. Exclusive refers to Licensed Patents only. Know-how, data and other materials licensed are provided on a non-exclusive basis only.
License Property
Licensor Inventions related to 'Multiple Novel Androgen Receptor Variants as Biomarkers and Therapeutic Targets for Androgen Refractory Human Prostate Cancer' and 'Methods and Compositions Related to Prostate Cancer Therapeutics'.

Licensed Patent means (a) U.S. Provisional Patent Application Nos. 62/041,368, 61/124,359. 61/124,328, 61/114,153 International Patent Application No. PCT/US2009/02392 U.S. Patent Application No. 12/988,299, Canadian Patent Application No. 2,721,506 and European Patent Application No. 09733012.0 and the inventions disclosed and claimed therein

Technology related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company’s lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.

Field of Use
Inventions related to certain assays to identify androgen receptor variants for use as a companion diagnostic with galeterone.

Galeterone is a highly selective, multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The pathway is ordinarily activated by the binding of male hormones, or androgens, such as testosterone and the more potent androgen dihydrotestosterone, or DHT, to the ligand binding domain of androgen receptors in prostate cancer cells. Galeterone disrupts the activation of the pathway through multiple mechanisms of action.

Field of Use companion diagnostic for Galeterone (excluding commercial sale as research reagent).

IPSCIO Record ID: 256217

License Grant
In the original agreement Licensor, government public health organization, grants an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.

The Licensor grants a co-exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use. For purposes of this Agreement co-exclusive shall mean that at any time only the Licensee and its Affiliates, on the one hand, and one other Licensee and its Affiliates, on the other hand, shall at any time have a license or other right from the Licensor under the Licensed Patent Rights in the Licensed Territory in the Licensed Fields of Use.

License Property
The agreement is for a specified constructs, formulations and doses of specified Licensed Products in a specified cancer indication, the statistical demonstration in a pivotal Phase 3 Clinical Study of safety and efficacy, sufficient to support a BLA submission by the Licensee for such specified construct, formulation and dose of such specified Licensed Product for the treatment of such specified cancer indication.
Field of Use
Licensed Fields of Use, defined in the original agreeement is
–  Development and manufacture of synovial sarcoma breakpoint X-2 (SSX-2) T cell receptor (TCR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of head and neck cancer, hepatocellular carcinoma, melanoma, prostate cancer, and sarcoma.
–  Development and manufacture of epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of brain cancer, head and neck cancer, and melanoma.
–  Development and manufacture of synovial sarcoma breakpoint X-2 (SSX-2) T cell receptor (TCR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of breast cancer, ovarian cancer, and colorectal cancer.
–  Development and manufacture of epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of breast cancer, ovarian cancer, and colorectal cancer.
For purposes of the Agreement, autologous peripheral blood T cell therapy products shall mean T cell or precursor products and compositions derived from blood, bone marrow, lymph nodes and thymus and, for the avoidance of doubt, shall exclude tumor-infiltrating lymphocytes (TILs).

IPSCIO Record ID: 28618

License Grant
Licensor hereby grants to Swiss Licensee and its Affiliates an exclusive, royalty-bearing license in the Territory, with the right to sublicense, under Celgene Patent Rights, Licensor's interest in Joint Patent Rights and Know-How of Licensor to develop, make, have made, use, sell, offer for sale and import Products in all Fields of Use, and non-exclusive, non-transferable, royalty-free research license in the Territory under Licensor Patent Rights, Licensor's interest in Joint Patent Rights and Know-How of Licensor solely for the purpose of conducting research on Research Compounds, Active Compounds, Candidate Compounds, Final Selected Compounds and Back-Up Compounds in all Fields of Use; provided, however, that

Licensor and its Affiliates developed expertise and acquired proprietary rights related to selective estrogen receptor modulator compounds ('SERMS') which are selective for Estrogen Receptor ('ER')(alpha) ('ER(alpha)') in U2OS cells (the 'ER(alpha)SELECTIVITY'

License Property
SP500263  Series  shall mean  Licensor's  proprietary  compounds claimed in U.S. Patent Application  Serial No.  09/475,776
Field of Use
Additional Field shall mean the treatment, prevention and diagnosis of a disease or disorder, other than a disease or disorder within the Primary Field or the Oncology Field.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.